Inhaled nitric oxide prevents experimental platelet activating factor-induced shock.
OBJECTIVE
To investigate whether inhaled nitric oxide (INO) can prevent platelet activating factor (PAF)-induced pulmonary hypertension and shock.


METHODS
Randomized controlled animal trial.


METHODS
Laboratory.


METHODS
Yorkshire swine.


METHODS
Animals received general anesthesia and invasive hemodynamic monitoring, then PAF only, 2.5 micrograms/kg intravenously over 45 minutes (PAF group, n = 9) or PAF in addition to INO, 20 ppm (PAF-INO group, n = 6).


RESULTS
Vascular pressures (mean arterial and mean pulmonary), vascular resistance indexes (systemic and pulmonary), cardiac indexes, and oxygen delivery and oxygen consumption.


RESULTS
Mean arterial pressures, cardiac indexes, and oxygen delivery and consumption were significantly higher in the PAF-INO group. Mean pulmonary arterial pressures and systemic and pulmonary vascular resistance indexes were significantly lower in the PAF-INO group. There were 4 deaths (44%) in the PAF group vs none (0%) in the PAF-INO group (P = 10).


CONCLUSIONS
The use of INO prevents pulmonary hypertension, circulatory failure, and death during PAF-induced shock.
Emil
S
S
Division of Pediatric Surgery, Childrens Hospital, Los Angeles, Calif, USA.
Berkeland
J
J
Kosi
M
M
Atkinson
J
J
D000280:Administration, Inhalation; D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006439:Hemodynamics / Q000187:drug effects; D006976:Hypertension, Pulmonary / Q000139:chemically induced / Q000188:drug therapy*; D009569:Nitric Oxide / Q000627:therapeutic use*; D010972:Platelet Activating Factor / Q000009:adverse effects*; D011897:Random Allocation; D012772:Shock, Septic / Q000139:chemically induced / Q000188:drug therapy*; D013552:Swine
D010972:Platelet Activating Factor; D009569:Nitric Oxide